急性早幼粒白血病细胞ATRA耐药株HL-60R、NB4R的构建及鉴定-东南大学学报医学版

急性早幼粒白血病细胞ATRA耐药株HL-60R、NB4R的构建及鉴定

单位：东南大学医学院病原生物学与免疫学系, 发育与疾病相关基因教育部重点实验室, 江苏南京 210009

分类号：R-33;R733.71

出版年·卷·期（页码）：2014·33·第五期（569-572）

摘要：

目的：构建急性早幼粒细胞白血病细胞系HL-60、NB4的全反式维甲酸耐药株HL-60R、NB4R，并对其生物学性状进行鉴定。方法：以全反式维甲酸（ATRA）为诱导药物，采用浓度递增间歇诱导法构建HL-60、NB4细胞相应的ATRA耐药株。CCK8法鉴定其ATRA耐药性，并检测耐药细胞株的生长曲线及多药耐药性。结果：成功构建了ATRA耐药细胞株HL-60R、NB4R，并发现与亲代细胞相比，其生长增殖速度减慢，群体倍增时间延长，且对其它多种化疗药物产生一定程度的交叉耐药。结论：成功构建的耐药细胞系HL-60R、NB4R为急性早幼粒细胞白血病多药耐药机制的进一步研究奠定了基础。

Objective: To establish human acute promyelocytic leukemia (APL) ATRA-resistant cell lines and to explore their biological characteristics. Methods: Human APL ATRA-resistant cell lines HL-60R and NB4R were established by stepwise increasing concentrations of ATRA selection from the parental cell lines HL-60 and NB4.Drug sensitivity of resistant cells was detected by CCK8 assay,and the changes of biological characteristics were determined by light microscopy and cell counting. Results: Human APL ATRA-Resistant cell lines HL-60R and NB4R were developed with stable resistance to ATRA.Compared to parental cells,HL-60R and NB4R cells grew more slowly and had a longer doubling time. Besides,HL-60R and NB4R cells exhibited cross-resistance to etoposide, vincristine sulfate, cytarabine and doxorubicin. Conclusion:HL-60R and NB4R cells are reliable multi-drug resistant cell sublines of APL.The successful establishment of these cells has laid a solid foundation for further study of the multi-drug resistant mechanism of human APL induced by ATRA.

参考文献：

[1] SHAFFER B C,GILLET J P,PATEL C,et al.Drug resistance:still a daunting challenge to the successful treatment of AML.Drug Resistance Updates,2012,15(1-2):62-69.
[2] LALLEMAND-BREITENBACH V,ZHU J,CHEN Z,et al.Curing APL through PML/RARA degradation by As₂O₃.Trends in Molecular Medicine,2012,18(1):36-42.
[3] FANG J,CHEN S J,TONG J H,et al.Treatment of acute promyelocytic leukemia with ATRA and As₂O₃:a model of molecular target-based cancer therapy.Cancer Biology & Therapy,2002,1(6):614-620.
[4] 贺白,顾伟英,曹祥山,等.急性早幼粒细胞白血病患者早期死亡的临床分析[J].现代医学,2011,39(2):169-172.
[5] 蔡倩,徐酉华,刘筱梅,等.HSP90β在ATRA诱导的白血病细胞株HL60耐药中的作用研究[J].重庆医科大学学报,2010,35(11):1658-1661.
[6] 薛芳,成志勇,杨琳,等.白血病耐药细胞系U937/ADR的建立及其生物学性状[J].中国生物工程杂志,2009,29(7):17-21.
[7] 陈新峰,杨菁.用MTT法进行白血病体外药物敏感性检测的临床意义[J].福建医科大学学报,2009,43(2):169-171,177.
[8] 苏祖禄,苏海,张毅,等.脑胶质瘤化疗药物的体外敏感性试验研究[J].第三军医大学学报,2013,35(13):1420-1423.
[9] SANZ M A,LO-COCO F.Modern approaches to treating acute promyelocytic leukemia.Journal of Clinical Oncology,2011,29(5):495-503.
[10] CORNELL R F,PALMER J.Adult acute leukemia.Disease-a-month :DM,2012,58(4):219-238.
[11] ARTEAGA M F,MIKESCH J H,QIU J,et al.The histone demethylase PHF8 governs retinoic acid response in acute promyelocytic leukemia.Cancer Cell,2013,23(3):376-389.
[12] 陈赛娟.白血病发病原理和靶向治疗研究——从急性早幼粒细胞到其他类型白血病[J].中华血液学杂志,2010,31:3-6.
[13] 张南文,许建华.人结肠癌耐药细胞系SW480/L-OHP的建立及其耐药机制初探[J].福建医科大学学报,2013(4):228-231.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录